659

C OPYRIGHT  2012 BY T HE J OURNAL OF B ONE AND J OINT S URGERY, I NCORPORATED

Current Concepts Review

Pathophysiology and New Strategies for the
Treatment of Legg-Calvé-Perthes Disease
Harry K.W. Kim, MD, MS, FRCSC

Investigation performed at Texas Scottish Rite Hospital for Children, Dallas, Texas

ä Legg-Calvé-Perthes disease is a juvenile form of idiopathic osteonecrosis of the femoral head that can lead to
permanent femoral head deformity and premature osteoarthritis.

ä According to two recent multicenter, prospective cohort studies, current nonoperative and operative treatments
have modest success rates of producing a good outcome with a spherical femoral head in older children with Legg-
Calvé-Perthes disease.

ä Experimental studies have revealed that the immature femoral head is mechanically weakened following ischemic
necrosis.

ä Increased bone resorption and delayed new bone formation, in combination with continued mechanical loading of
the hip, contribute to the pathogenesis of the femoral head deformity.

ä Biological treatment strategies to improve the healing process by decreasing bone resorption and stimulating
bone formation appear promising in nonhuman preclinical studies.

Legg-Calvé-Perthes disease is a juvenile form of idiopathic
osteonecrosis of the femoral head that affects children between
the ages of two and fourteen years. It is considered one of the
most common forms of pediatric femoral head osteonecrosis,
with the prevalence ranging from 5.1 to 16.9 per 100,000 in
various regions of the world1-4. Since the initial reports of this
unique condition approximately 100 years ago by Legg5, Calvé6,
and Perthes7, a number of studies have been published re-
garding its etiology 8-15, epidemiology1,3,4, natural history16-20,
radiographic classifications16,21-23, treatments24-29, and outcomes30-32.
Despite the increase in knowledge, Legg-Calvé-Perthes dis-
ease remains one of the most controversial conditions in
pediatric orthopaedics. Many aspects of the disease remain
unknown or unclear, including the etiology and pathophys-
iology of the disease and the best methods to treat the patients
in different age groups affected with the disease. The pur-
poses of this review are threefold: to provide an update on the
outcomes of current treatments according to the results of
recent prospective studies, to provide an update on the path-
ophysiology of Legg-Calvé-Perthes disease on the basis of the
knowledge gained from recent experimental investigations, and
to summarize the rationale, results, and concerns of new bio-
logical therapeutic strategies that are being explored as possible
treatments for the disease.
Current Treatments and Outcomes
Current treatments for Legg-Calvé-Perthes disease are largely
based on the principles of obtaining and maintaining good hip
range of motion, and obtaining and maintaining containment
of the femoral head in the acetabulum33,34. It is believed that, if
these principles are followed, a soft femoral head will be molded
into a spherical shape by the acetabular socket. Over the years,

Disclosure: The author did not receive payments or services, either directly or indirectly (i.e., via his institution), from a third party in support of any aspect
of this work. Neither the author nor his institution has had any financial relationship, in the thirty-six months prior to submission of this work, with any
entity in the biomedical arena that could be perceived to influence or have the potential to influence what is written in this work. The author has had a
relationship, or has engaged in another activity, that could be perceived to influence or have the potential to influence what is written in this work. The
complete Disclosures of Potential Conflicts of Interest submitted by authors are always provided with the online version of the article.

J Bone Joint Surg Am. 2012;94:659-69 d http://dx.doi.org/10.2106/JBJS.J.01834

 660
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E

tients with the onset of the disease before the age of six years
TABLE I Stulberg Radiographic Outcome of Three Treatments and from 20% to 43% in the 146 patients with the onset of the
in the Study by Herring et al.*
disease after the age of six years. While that study found that a
Radiographic Outcome femoral osteotomy was beneficial in the patients who were
According to Stulberg more than six years old at the onset of the disease, the effec-
Class
tiveness of a femoral osteotomy in achieving a spherical femoral
I or II III, IV, or V head was also modest.
The results of these studies raise a question regarding
Age of 6 to 8 years at disease
why a femoral or Salter innominate osteotomy produces good
onset (n = 204)
results in some patients and not in the others. One theory is
No treatment (n = 11) 27% (3) 73% (8)
that while these osteotomies do provide some load-relieving
Range of motion (n = 44) 48% (21) 52% (23)
effects on the necrotic femoral head42,45, they do not directly or
Brace (n = 79) 62% (49) 38% (30)
specifically address the pathobiology of the disease and the
Innominate osteotomy (n = 39) 69% (27) 31% (12)
impaired healing observed in the older children with Legg-
Femoral osteotomy (n = 31) 68% (21) 32% (10)
Calvé-Perthes disease. These results also clearly indicate a need
Age of ‡8 to 12 years at disease to develop more effective treatments for the disease that pre-
onset (n = 141)
vent the femoral head deformity. It is generally agreed that a
No treatment (n = 8) 25% (2) 75% (6)
better understanding of the pathophysiology of the femoral
Range of motion (n = 33) 30% (10) 70% (23)
head deformity in Legg-Calvé-Perthes disease is essential for
Brace (n = 50) 36% (18) 64% (32)
the development of more effective treatments.
Innominate osteotomy (n = 29) 41% (12) 59% (17)
Femoral osteotomy (n = 21) 62% (13) 38% (8)
Pathophysiology of Legg-Calvé-Perthes Disease
Various theories on the etiology of Legg-Calvé-Perthes disease
*The data are from Herring JA, Kim HT, Browne R. Legg-Calvé-
Perthes disease. Part II: Prospective multicenter study of the effect have been proposed. These include trauma, an inflammatory
of treatment on outcome. J Bone Joint Surg Am. 2004;86:2121-34. process, vascular occlusion, thrombophilia, insulin-like growth
factor-1 pathway abnormality, maternal smoking, second-hand
smoke exposure13,46-49, and, most recently, a subtle type-II col-
various nonoperative28,35-39 and operative treatments24,27,29,40,41 lagen mutation12,14,50. Most of these theories remain unsub-
were introduced on the basis of this concept. One of the crit- stantiated. Thrombophilia as a cause of Legg-Calvé-Perthes
icisms of this concept has been the inability to accurately disease remains controversial, with some studies having shown
quantify femoral head containment and to establish a direct an association between the disease and various coagulation factor
relationship between the amount of containment of the fem- abnormalities8,51-55, while other studies have shown no association
oral head and the ultimate outcome. According to hip mod-
eling studies42,43, a clinical impression of containment based on
radiographic assessment of the femoral head coverage may not
accurately represent the degree of containment of the femoral TABLE II Stulberg Radiographic Outcome of Three Treatments
Studied by Wiig et al.*
head.
The effectiveness of current treatments based on the Radiographic Outcome
concept of containment has been investigated in two multi- According to Stulberg Class
center prospective investigations (level-II prospective cohort I or II III, IV, or V
studies)30,44. In the study by Herring et al.30 (Table I), the success
rate of achieving a spherical femoral head (Stulberg class-I Age of <6 years at diagnosis
or II hips)20 after one of the five treatments (no treatment, (n = 168)
physiotherapy, Scottish Rite orthosis, femoral osteotomy, or Physiotherapy (n = 123) 53% (65) 47% (58)
Salter innominate osteotomy29) ranged from 27% to 69% in Scottish Rite orthosis (n = 22) 45.5% (10) 54.5% (12)
the 204 patients with the onset of the disease between the ages Femoral osteotomy (n = 23) 52% (12) 48% (11)
of six and eight years and from 25% to 62% in the 141 patients Age of ‡6 years at diagnosis
with the onset of the disease between the ages of eight and (n = 146)
twelve years. The operative treatments, as a treatment group, Physiotherapy (n = 51) 33% (17) 67% (34)
produced better results than the nonoperative treatments Scottish Rite orthosis (n = 25) 20% (5) 80% (20)
for the older age group; however, the effectiveness of these Femoral osteotomy (n = 70) 43% (30) 57% (40)
treatments in achieving a spherical femoral head was mod-
est. In the study by Wiig et al.44 (Table II), the success rate of *Data are from Wiig O, Terjesen T, Svenningsen S. Prognostic
factors and outcome of treatment in Perthes’ disease. A pro-
achieving a spherical femoral head after one of the three spective study of 368 patients with five-year follow-up. J Bone Joint
treatments (physiotherapy, Scottish Rite orthosis, or femoral Surg Br. 2008;90:1364-71.
varus osteotomy) ranged from 46% to 53% in the 168 pa-
 661
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
at all11,56-60. The prevailing opinion is that Legg-Calvé-Perthes dis-
ease is a multifactorial disease with genetic and environmental
factors playing a role. There is also the possibility that the disease is
caused by several etiological factors that share a common patho-
logical and clinical presentation.
Regardless of the cause, a disruption of blood supply to
the femoral head, producing ischemic necrosis, appears to be a
key pathogenic event, leading to the pathological and subse-
quent structural changes to the growing femoral head. Diag-
nostic imaging studies, such as selective angiography61-63, bone
scintigraphy64, and gadolinium-enhanced magnetic resonance
imaging65, provide evidence of absent blood flow to the affected
femoral head. Although histological studies of the femoral head
and biopsy specimens from the patients with Legg-Calvé-Perthes
disease are limited in number, they show changes consistent with
ischemic necrosis of the bone and the deep layer of the articular
cartilage66,67. Animal studies also have shown that a disruption of
the blood supply to the femoral head can produce radiographic
and histological changes resembling Legg-Calvé-Perthes disease68,69.
The question of whether Legg-Calvé-Perthes disease is
due to a single episode of infarction or multiple episodes of
infarction remains controversial. The evidence for the single
infarction theory comes from studies of immature pigs in
which one episode of ischemia induction surgery produced
radiographic and histological changes resembling Legg-Calvé-
Perthes disease. The evidence for the multiple infarction theory
comes from studies on immature dogs in which a single epi-
sode of infarction did not produce femoral head necrosis or
deformity, while consecutive interruptions of the blood supply
produced changes resembling Legg-Calvé-Perthes disease in
some femoral heads70,71. In a subsequent clinical study, 51% of
fifty-seven biopsy specimens from the femoral heads of patients
with the disease revealed dead woven bone superimposed on
dead lamellar bone with the marrow space occupied by dead
granulation tissue, suggesting two episodes of infarction72.
Catterall et al. also observed thickened trabeculae with many
cement lines in the central area of two femoral heads with total
head involvement (Group 4 in the Catterall classification)66.
However, in the periphery of the specimens with less femoral
head involvement (Group 1 in the Catterall classification), the
authors observed osseous trabeculae showing only one episode
of infarction. One interpretation of these findings is that
multiple episodes of infarction are necessary to produce Legg-
Calvé-Perthes disease. This interpretation suggests that, if the
cause of the infarction episodes can be identified, and if in-
tervention can be initiated early in the course of the disease
process, then a full-blown disease may be prevented or the
severity of the disease can be reduced. Another interpretation
of these findings is that the disease is due to one infarction
episode, but subsequent mechanical overloading may injure
the vessels in the healing areas of the femoral head or produce
intermittent compression of the blood vessels traversing the
cartilage in the area of high loading, producing secondary
episodes of infarction. This interpretation suggests that the
prevention of mechanical overloading and a femoral head de-
formity would be beneficial to the healing process.
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E
Pathogenesis of Femoral Head Deformity
in Legg-Calvé-Perthes Disease
Development of the femoral head deformity is the most im-
portant sequela of Legg-Calvé-Perthes disease since the extent
of the deformity correlates with the long-term outcome18-20. A
serial radiographic examination of patients with the disease
demonstrates that the development of the deformity begins in
the initial stage of the disease (the stage of increased radio-
density) and progresses during the resorptive stage (the stage of
fragmentation). From the limited number of biopsy and nec-
ropsy studies of Legg-Calvé-Perthes disease, various patho-
logical changes from the proximal part of the femur that
include the articular cartilage, osseous epiphysis, physis, and
metaphysis have been reported66,67,73-76. The temporal sequence
of the pathological changes and the functional importance of
the changes are difficult to appreciate from these few studies
as they only examined a limited number of specimens and in
various stages of the disease.
The lack of availability of clinical samples for research has
prompted an alternative approach, the use of experimental
models, to investigate the pathogenesis of the femoral head
deformity. In particular, a piglet model has allowed more sys-
tematic and in-depth investigation. This model of ischemic
necrosis of the immature femoral head is created by applying a
ligature (resorbable suture) around the femoral neck to disrupt
the blood flow to the femoral head. The femoral head becomes
necrotic and remains avascular in the first two weeks (the
avascular stage). Revascularization and resorption of the ne-
crotic head are initiated by three to four weeks after ischemia
induction (the vascular repair stage), and moderate to severe
femoral head deformity is observed at eight weeks after is-
chemia induction68. The studies of this model have revealed
that the pathogenesis of the femoral head deformity following
ischemic necrosis is complex, and multiple factors contribute
to the development of the deformity68,77-80 (Fig. 1). Mechanical
testing of the normal and the infarcted femoral heads from
immature pigs has revealed a significant and persistent decrease
in the mechanical properties of the infarcted head from the
early avascular stage to the later vascular repair stage in this
model80. Further studies have revealed that the mechanical
properties of the articular cartilage and the bone from the in-
farcted heads were decreased79. Proposed explanations for the
early compromise of the mechanical properties have included
the necrosis of the deep layer of the articular cartilage as a result
of the ischemic injury, the inability of the necrotic bone to
repair the microdamage incurred during normal loading of the
hip, and the changes in the material properties of the calcified
cartilage and the subchondral bone associated with the ische-
mic damage. A recent study on the mineral content of the ne-
crotic trabecular bone, with use of a technique called quantitative
backscatter electron imaging, showed a significant increase in
the calcium content of the calcified cartilage and the sub-
chondral bone (p < 0.05), making the bone more homoge-
neous in the calcium content and, likely, more brittle77. It is
postulated that since brittle bone is more prone to micro-
damage and since there are no osteoclasts and osteoblasts in
 662
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
Fig. 1
A flowchart depicting the pathogenesis of the femoral head deformity in Legg-Calvé-Perthes disease. VEGF = vascular endothelial growth factor.
the necrotic regions of bone to repair the microdamage in-
curred with the normal activities, this microdamage accu-
mulates and results in a subchondral fracture or a compaction
fracture with continued loading of the hip in the early stages
of Legg-Calvé-Perthes disease.
In the vascular repair stage of the piglet model, a path-
ological repair process marked by a predominance of osteo-
clastic resorption and delayed bone formation contributes to
the pathogenesis of the deformity68 (Fig. 2). The uncoupling of
bone resorption and formation, and the replacement of the
necrotic bone by a fibrovascular granulation tissue, impart
further weakening to the femoral head. The repair process is
clearly not ‘‘creeping substitution,’’ as defined by Phemister, in
which dead bone is substituted by new bone in the infarcted
segment of adult femoral heads81. The uncoupling of bone
resorption and formation observed in the piglet model is also
observable in the patients with Legg-Calvé-Perthes disease. The
resorptive stage or the stage of fragmentation in the disease
demonstrates increased bone resorption seen as radiolucent
areas on serial radiographs prior to the femoral head entering
the stage of reossification several months or more after the
appearance of the radiolucent areas. Femoral head specimens
obtained from the patients at the stage of fragmentation indeed
show an increased presence of osteoclasts in the areas of repair
and replacement of the bone with a fibrovascular tissue66,67. The
pathological repair process (imbalance of resorption and for-
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E
mation) has been recognized by several investigators as a po-
tential therapeutic target to improve the remodeling of the
necrotic bone and to prevent the development of the deformity
in the immature femoral head82-86.
In addition to these mechanisms, ischemic necrosis of
the immature femoral head produces a growth arrest of the
spherical growth plate surrounding the osseous epiphysis,
which can potentially worsen the femoral head deformity (Fig.
2). Histological studies of specimens from patients with Legg-
Calvé-Perthes disease66,74,76 and the experimental models of
ischemic necrosis78,87,88 have shown necrosis of the deep layer
of the articular cartilage, where endochondral ossification
of the osseous epiphysis occurs. To obtain normal spherical
growth of the epiphysis, endochondral ossification of the osse-
ous epiphysis must be restored in a symmetric, circumferential
fashion as distorted, asymmetric growth may further contribute
to the head deformity. At the present time, the mechanisms
involved with the restoration of the epiphyseal growth are
poorly understood; however, vascular endothelial growth
factor appears to be involved in this process as it is increased
in the cartilage overlying the necrosis in the experimental
studies89,90. It is also known to play an important role in angio-
genesis and endochondral ossification91. A recent experimental
study has suggested that exogenous bone morphogenetic
protein (BMP)-2 administration may hasten the restorative
process92.
 663
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E

Fig. 2
A drawing representing a normal femoral head and an infarcted femoral head in an early stage of revascularization. Ischemic necrosis produces extensive
cell death in the deep layer of the articular cartilage. This is the growth cartilage responsible for the circumferential growth of the secondary center of
ossification. The ischemic damage produces a growth arrest of the secondary center, which may not be restored symmetrically during the healing process
and produces growth disturbance of the secondary center. Revascularization of the infarcted femoral head is associated with a predominance of resorptive
activity, as shown in the drawing. (Reproduced, with permission, from: the Texas Scottish Rite Hospital for Children, Dallas, Texas.)

Role of Hip Loading on the Pathogenesis of Femoral
Head Deformity
Since the hip is a major load-bearing joint, the contribution of
mechanical loading to the pathogenesis of the deformity in
Legg-Calvé-Perthes disease must be considered. Unfortunately,
very little is known about the hip forces associated with various
activities of daily living in children. In adults, however, the hip
contact pressures have been measured in a limited number of
patients who had implantation of a strain gauge-instrumented
hip replacement with a telemetric capability to transmit hip
contact forces in real time93,94. These studies have shown that
substantial loading of the hip occurs with normal daily ac-
tivities. For instance, walking at a normal rate can produce hip
forces of approximately 2.5 times the body weight with each
step, while running can produce hip contact pressure of ap-
proximately five times the body weight with each stride. Along
with the magnitude of loading, the frequency of loading may
be important as an active child can take >7500 steps per day
on average95. While it is reasonable to postulate that loading
of the necrotic head contributes to the worsening of the de-
formity, the efficacy of restricting activities to prevent pro-
gression of the deformity is not well studied and it remains
controversial.
Antiresorptive Therapy To Inhibit Pathological
Resorption of the Necrotic Bone
Recognition of Legg-Calvé-Perthes disease as having an im-
portant resorptive component contributing to the femoral
head deformity has led investigators to study the effects of
inhibiting osteoclast-mediated bone resorption on preventing
the deformity. The most direct evidence that osteoclastic re-
sorption plays an important role in the development of the
deformity comes from a large-animal study that used exoge-
nous osteoprotegerin (OPG), a natural soluble decoy receptor
of the receptor activator of nuclear factor (NF)-kß ligand
(RANKL)83. It is well established that the interaction of the
receptor activator of NF-kß (RANK) and its ligand, RANKL, is
essential for osteoclast formation, function, and activation96.
The binding of OPG to RANKL prevents the RANK-RANKL
interaction and effectively inhibits osteoclast formation, ac-
tivation, and survival. In a piglet model of ischemic necrosis,
exogenous OPG therapy significantly decreased osteoclast
number (p < 0.001), bone resorption (p < 0.001), and femoral
head deformity (p < 0.001), providing evidence that specific
targeting of osteoclastogenesis and osteoclastic function can
positively modulate the outcome in this model (Fig. 3)68.
Recently, a RANKL inhibitor called denosumab, a mono-
clonal antibody to RANKL, has become clinically available
for the treatment of postmenopausal osteoporosis97. Its ef-
fect on femoral head osteonecrosis, however, has not been
investigated.
More extensive studies have been performed with use of
bisphosphonates, which are well-known inhibitors of osteo-
clastic resorption82,84-86,98,99. The mechanism of action of the
aminobisphosphonates (the newer bisphosphonates) is to in-
hibit farnesyl pyrophosphatase, an enzyme in the HMG-CoA
 664
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E

Fig. 3
Fig. 3-A Radiographs of the central region of immature femoral heads showing a progression of the femoral head deformity in the piglet model. w = weeks
following the induction of ischemic necrosis. Fig. 3-B A microcomputed tomographic image of a central region of the femoral head obtained at three weeks
after the induction of ischemia, showing a circular area of bone resorption in the necrotic epiphysis. A radiodense, intravascular contrast material (Microfil;
Flow Tech, Carver, Massachusetts) was infused into the distal aorta before imaging to detect revascularization in the necrotic epiphysis. The arrow is
pointing to a vessel with multiple small branches within the area of resorption. Fig. 3-C A photomicrograph of a peripheral area of revascularization showing
the increased presence of multinucleated cells (osteoclasts) and resorption of the trabecular bone (hematoxylin and eosin staining, ·20). Fig. 3-D A
photomicrograph of a central area of revascularization showing fibrovascular tissue. The resorbed bone was not replaced by new bone (hematoxylin and
eosin staining, ·10). (Figs. 3-A and 3-C are reproduced from Kim HK, Su PH. Development of flattening and apparent fragmentation following ischemic
necrosis of the capital femoral epiphysis in a piglet model. J Bone Joint Surg Am. 2002;84:1329-34.)

(3-hydroxy-3-methylglutaryl-coenyzyme A) reductase path-
way, which interferes with prenylation of small GTPase pro-
teins98. The uptake of these drugs by osteoclasts inhibits their
resorptive activity and accelerates apoptosis. Unlike RANKL
inhibitors, bisphosphonates do not inhibit osteoclast forma-
tion. Experimental studies in immature rat85,86 and pig models
of ischemic necrosis84 have shown that systemically adminis-
tered bisphosphonates can decrease bone resorption and
femoral head deformity. In those studies, multiple dosing
regimens were used as only a small portion of each dose was
thought to access the necrotic femoral head. A study with use of
14C-labeled-ibandronate in immature pigs showed that the
local bioavailability and distribution of this bisphosphonate in
the necrotic head depended on the vascular status of the head99.
In the early avascular stage of the piglet model, very little ra-
dioactivity was detected in the necrotic head following an in-
travenous dose of 14C-labeled ibandronate. A significant
increase in the radioactivity was observed when the dose was
administered at a later stage when revascularization of the
femoral head had occurred (p < 0.05). These findings imply
that oral or intravenous administration of a bisphosphonate
has very limited access to the necrotic bone in the early stages of
the disease. Because of this limitation, a multiple-dosing regi-
men is thought to be required to allow accumulation of the
drug in the necrotic region with each dose100. The repeated
dosing over time is also thought to provide a greater oppor-
tunity for the drug to access the necrotic bone since the vascular
status of the necrotic head improves over time.
A concern for a wide distribution of bisphosphonate with
its long half-life on the immature skeleton and the limited
accessibility of the systemically administered bisphosphonate
on the infarcted head have led to an experimental investigation
on the retention, distribution, and effects of a local, intraos-
seous administration of bisphosphonate for the treatment of
femoral head osteonecrosis82,99. A single, local administration
was shown to be effective and substantially decreased the total
amount of bisphosphonate required to decrease the deformity
in immature pigs82. Only 5% of the systemic dose was required
in the local administration study compared with the systemic
administration study. While antiresorptive drugs were found to
be effective in preserving the necrotic bone in these studies,
their effect on bone remodeling and new bone formation has
been mixed. In rat models of osteonecrosis, new bone forma-
tion has been shown to occur on the necrotic bone surface85,86.
This has not been demonstrated in the piglet model. The os-
teoblast surface was significantly lower in the OPG (88%; p <
0.01) and the ibandronate treatment (93%; p < 0.05) groups
compared with their respective normal control groups83,84 (Fig.
 665
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E

Fig. 4
Fig. 4-A Radiographs of infarcted femoral heads in the animals treated with subcutaneous saline solution or osteoprotegerin (OPG-Fc), which inhibits
osteoclast formation, function, and activation. The treatments were initiated two weeks after the induction of ischemic necrosis. The OPG group had a
significantly better preservation of the femoral head, as indicated by the bar graph representing the mean epiphyseal quotient (ratio of femoral head height
to its diameter) and the standard deviation. *p < 0.001 compared with the other groups. Fig. 4-B Low-magnification (·0.5) photomicrographs of the femoral
heads from the control, saline solution, and OPG groups. The femoral heads from the saline solution group had areas of bone resorption (arrows) and
femoral head deformity. The femoral heads from the OPG group had significantly less bone resorption and better preservation of the femoral head shape
(McNeal tetrachromium staining). Fig. 4-C Higher-magnification (·10) photomicrographs of the femoral heads from the control, saline solution, and OPG
groups stained for osteoclasts (red stain) (tartrate-resistant acid phosphatase staining). The mean osteoclast number (and standard deviation) was
significantly lower in the OPG group, as shown on the bar graph. *p < 0.0001 compared with the other groups. (Reproduced, with permission, from: Kim HK,
Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res.
2006;21:1946-54. 2006 American Society for Bone and Mineral Research.)

4). At this point, it is unclear whether this is an issue of the
duration of follow-up or an issue of the antiresorptive agents
having an inhibitory effect on new bone formation due to a
coupling of the two processes.
Currently, the use of bisphosphonate therapy to treat
Legg-Calvé-Perthes disease is investigational. A randomized
clinical trial comparing intravenous administration of zole-
dronic acid and standard care (weight-bearing restriction and
current treatments) for Legg-Calvé-Perthes disease (clinical
trial registration ACTRN12610000407099) is under way in
Australia.
Bone Anabolic Therapy To Stimulate New
Bone Formation
The effects of BMP administration on bone formation in the
context of femoral head osteonecrosis are being investigated
since BMP-2 and BMP-7 are potent osteoinductive agents
shown to promote bone healing under difficult clinical cir-
cumstances101-103. The use of BMP-2 to stimulate healing as an
adjunct to core decompression or a strut graft has been in-
vestigated in adult animal models of osteonecrosis104,105 and
femoral head defect106. The animal studies have described im-
proved bone healing and increased new bone formation with
 666
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E

Fig. 5
Fig. 5-A Radiographs of the femoral head of animals treated with intraosseous saline solution, ibandronate (IB), or IB and bone morphogenetic protein
(BMP)-2. A single injection of the respective agent(s) was rendered one week following the induction of ischemic necrosis. Fig. 5-B Photomicrographs
showing osteoblasts (black arrows) on the surface of the trabecular bone in the IB 1 BMP-2 group and the normal, control group (red arrows). The femoral
heads from the saline and the IB groups had a lack of osteoblasts on the trabecular surfaces. Bars = 100 mm. Fig. 5-C A bar graph showing the mean
percentage (and standard deviation) of trabecular bone surface on which osteoblasts were attached, with a significantly greater osteoblast surface, an
indicator of bone formation, in the IB 1 BMP-2 group than in the saline solution and the IB groups. (Reproduced from: Vandermeer JS, Kamiya N, Aya-ay J,
Garces A, Browne R, Kim HKW. Local administration of ibandronate and bone morphogenetic protein-2 stimulates bone formation and decreases femoral
head deformity following ischemic osteonecrosis of the immature femoral head. J Bone Joint Surg Am. 2011;93:905-13.)

the BMP treatment. BMP-2 has also been used clinically to treat
femoral head osteonecrosis in adults as an adjunct to core
decompression107. In a case series of seventeen hips (sixteen
Ficat Stage-II hips and one Ficat Stage-III hip), three hips
progressed and required total hip replacement, while fourteen
hips had good results at an average follow-up duration of fifty-
three months107. Since the study was retrospective in nature
without a control group, the true efficacy of BMP-2 treatment
could not be determined.
The use of BMPs to treat femoral head osteonecrosis in a
pediatric population has not been reported, as far as we know.
However, a combined treatment of bisphosphonate (ibandro-
nate) and BMP-2 with use of a local intraosseous injection
technique has been reported in a large-animal study92 (Fig. 5).
The rationale for using bisphosphonate and BMP-2 together in
the study was that, along with osteoinductive properties,
BMP-2 is known to transiently stimulate osteoclastogenesis
and bone resorption108-111. In comparison with the group that
had local administration of ibandronate alone, the group that
had local administration of ibandronate and BMP-2 showed a
significantly greater percent of osteoblast surface on the tra-
becular bone (p < 0.0001), greater bone volume (p < 0.0001),
and remodeling of the necrotic femoral head92. Furthermore, in
three of the six femoral heads treated with ibandronate and
BMP-2, a restoration of growth of the epiphysis was observed.
Along with improved bone healing, the round shape of the
femoral heads was better preserved in the ibandronate and
BMP-2 treatment group compared with the saline solution
group. In that study, however, heterotopic ossification was
observed in the hip joint capsule of the animals treated with the
 667
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
ibandronate and BMP-2. It is postulated that a leakage of BMP-
2 into the joint on removal of the injection needle and injection
of BMP-2 shortly after the surgical trauma to create the femoral
head ischemia may have predisposed the soft tissues around the
hip to heterotopic ossification. The use of BMPs to treat Legg-
Calvé-Perthes disease is still experimental at this time, and
further studies are warranted prior to the use of BMPs to treat
children with femoral head osteonecrosis.
Clinical Studies on Bisphosphonate Therapy for Femoral
Head Osteonecrosis
To date, only a small number of studies have investigated the
effects of bisphosphonate therapy for the treatment of femoral
head osteonecrosis112-117. Most of those studies assessed short-
term outcomes in adults with nontraumatic femoral head
osteonecrosis. Four clinical studies on nontraumatic osteo-
necrosis in adults have shown some beneficial effects of bis-
phosphonate therapy on pain, function, and preservation of
the femoral head112-115. It is of note that, in the randomized
clinical trial reported by Lai et al., only two of twenty-nine hips
required total hip replacement following oral alendronate
therapy for six months compared with nineteen of twenty-five
hips in the nontreatment group at the minimum follow-up
period of two years114. A study by Agarwala et al. showed that
oral bisphosphonate therapy produced the best results when
initiated in the early stage of osteonecrosis (stage-1 disease). At
the mean follow-up interval of four years, 56% (seventy-two)
of 129 patients with stage-2 disease had a radiographic evidence
of collapse, whereas only 13% (twenty-seven) of 215 patients
with stage-1 disease had a collapse113. Limitations of that study
were that the extent of the head involvement was not assessed
and that there were no controls.
A prospective case series of adolescent patients who had
traumatic osteonecrosis because of unstable slipped capital
femoral epiphysis, hip fracture, or dislocation showed that
those who had a cold bone scan and who were treated with
intermittent intravenous bisphosphonate therapy over an av-
erage period of twenty months did reasonably well at the
minimum follow-up of two years116. Nine of seventeen patients
had a spherical femoral head, and fourteen of seventeen pa-
References
1. Gray IM, Lowry RB, Renwick DH. Incidence and genetics of Legg-Perthes disease
(osteochondritis deformans) in British Columbia: evidence of polygenic determina-
tion. J Med Genet. 1972;9:197-202.
2. Margetts BM, Perry CA, Taylor JF, Dangerfield PH. The incidence and distribution
of Legg-Calvé-Perthes’ disease in Liverpool, 1982-95. Arch Dis Child. 2001;84:
351-4.
3. Molloy MK, MacMahon B. Incidence of Legg-Perthes disease (osteochondritis
deformans). N Engl J Med. 1966;275:988-90.
4. Wiig O, Terjesen T, Svenningsen S, Lie SA. The epidemiology and aetiology of
Perthes’ disease in Norway. A nationwide study of 425 patients. J Bone Joint Surg Br.
2006;88:1217-23.
5. Legg A. An obscure affection of the hip joint. Boston Med Surg J. 1910;162:
202-4.
6. Calvé J. [On a particular form of pseudo-coxalgia associated with a characteristic
deformity of the upper end of the femur]. Rev Chir. 1910;42:54-84. French.
7. Perthes G. [Concerning arthritis deformans juvenilis]. Deutsche Zeitschr Chir.
1910;107:111-59. German.
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E
tients were pain-free. That study, however, did not have a
control group. A small study of seventeen patients with osteo-
necrosis as a complication of chemotherapy for childhood
leukemia has also been reported117. In general, improvements
in the pain scores, analgesic requirement, and function were
observed in the nine patients who received bisphosphonate
therapy; however, a radiographic benefit of the therapy could
not be demonstrated. In a small number of patients with Legg-
Calvé-Perthes disease, the systemic effects of intravenous bis-
phosphonate have been reported recently100; however, its ef-
fect on the preservation of the femoral head has yet to be
reported.
Overview
Multicenter prospective cohort studies (level-II evidence) have
shown that the benefits of treatment for older children affected
with Legg-Calvé-Perthes disease are modest, even with opera-
tive treatments. A better understanding of the pathogenesis of
the femoral head deformity is required to develop more ef-
fective treatments. Experimental studies have revealed that an
imbalance of bone resorption and bone formation plays an
important role in the development of the deformity. Further
studies are needed to address the questions about why there is
uncoupling of bone resorption and formation during the
remodeling of the necrotic femoral head, what molecular
mechanisms are involved, and how we can therapeutically
target them more effectively. While recent experimental studies
have shown that antiresorptive and anabolic agents can effec-
tively modulate the pathological repair process, further studies
are needed to address the clinical efficacy and safety of these
agents for the treatment of Legg-Calvé-Perthes disease. n
Harry K.W. Kim, MD, MS, FRCSC
Center for Excellence in Hip Disorders,
Department of Orthopaedic Surgery,
Texas Scottish Rite Hospital for Children,
UT Southwestern Medical Center, 2222 Welborn Street,
Dallas, TX 75218. E-mail address: Harry.kim@tsrh.org
8. Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, Mehlman CT,
Crawford AH. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am.
2004;86:2642-7.
9. Glueck CJ, Glueck HI, Greenfield D, Freiberg R, Kahn A, Hamer T, Stroop D, Tracy
T. Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic
causes of Legg-Perthes disease. Pediatr Res. 1994;35:383-8.
10. Hall DJ. Genetic aspects of Perthes’ disease. A critical review. Clin Orthop Relat
Res. 1986;209:100-14.
11. Hresko MT, McDougall PA, Gorlin JB, Vamvakas EC, Kasser JR, Neufeld EJ.
Prospective reevaluation of the association between thrombotic diathesis and legg-
perthes disease. J Bone Joint Surg Am. 2002;84:1613-8.
12. Miyamoto Y, Matsuda T, Kitoh H, Haga N, Ohashi H, Nishimura G, Ikegawa S.
A recurrent mutation in type II collagen gene causes Legg-Calvé-Perthes disease in
a Japanese family. Hum Genet. 2007;121:625-9.
13. Neidel J, Zander D, Hackenbroch MH. Low plasma levels of insulin-like growth
factor I in Perthes’ disease. A controlled study of 59 consecutive children. Acta
Orthop Scand. 1992;63:393-8.
 668
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
14. Su P, Li R, Liu S, Zhou Y, Wang X, Patil N, Mow CS, Mason JC, Huang D, Wang Y.
Age at onset-dependent presentations of premature hip osteoarthritis, avascular
necrosis of the femoral head, or Legg-Calvé-Perthes disease in a single family,
consequent upon a p.Gly1170Ser mutation of COL2A1. Arthritis Rheum.
2008;58:1701-6.
15. Wynne-Davies R, Gormley J. The aetiology of Perthes’ disease. Genetic, epi-
demiological and growth factors in 310 Edinburgh and Glasgow patients. J Bone
Joint Surg Br. 1978;60:6-14.
16. Catterall A. The natural history of Perthes’ disease. J Bone Joint Surg Br.
1971;53:37-53.
17. Gower WE, Johnston RC. Legg-Perthes disease. Long-term follow-up of thirty-six
patients. J Bone Joint Surg Am. 1971;53:759-68.
18. McAndrew MP, Weinstein SL. A long-term follow-up of Legg-Calvé-Perthes dis-
ease. J Bone Joint Surg Am. 1984;66:860-9.
19. Mose K. Methods of measuring in Legg-Calvé-Perthes disease with special
regard to the prognosis. Clin Orthop Relat Res. 1980;150:103-9.
20. Stulberg SD, Cooperman DR, Wallensten R. The natural history of Legg-Calvé-
Perthes disease. J Bone Joint Surg Am. 1981;63:1095-108.
21. Waldenstrom H. The definitive forms of coxa plana. Acta Radiol. 1922;1:384.
22. Herring JA, Neustadt JB, Williams JJ, Early JS, Browne RH. The lateral pillar
classification of Legg-Calvé-Perthes disease. J Pediatr Orthop. 1992;12:143-50.
23. Salter RB, Thompson GH. Legg-Calvé-Perthes disease. The prognostic signifi-
cance of the subchondral fracture and a two-group classification of the femoral head
involvement. J Bone Joint Surg Am. 1984;66:479-89.
24. Axer A. Subtrochanteric osteotomy in the treatment of Perthes’ disease: a
preliminary report. J Bone Joint Surg Br. 1965;47:489-99.
25. Brotherton BJ, McKibbin B. Perthes’ disease treated by prolonged recumbency
and femoral head containment: a long-term appraisal. J Bone Joint Surg Br.
1977;59:8-14.
26. Joseph B, Rao N, Mulpuri K, Varghese G, Nair S. How does a femoral varus
osteotomy alter the natural evolution of Perthes’ disease? J Pediatr Orthop B.
2005;14:10-5.
27. Kruse RW, Guille JT, Bowen JR. Shelf arthroplasty in patients who have Legg-
Calvé-Perthes disease. A study of long-term results. J Bone Joint Surg Am.
1991;73:1338-47.
28. Petrie JG, Bitenc I. The abduction weight-bearing treatment in Legg-Perthes’
disease. J Bone Joint Surg Br. 1971;53:54-62.
29. Salter RB. The present status of surgical treatment for Legg-Perthes disease.
J Bone Joint Surg Am. 1984;66:961-6.
30. Herring JA, Kim HT, Browne R. Legg-Calve-Perthes disease. Part II: prospective
multicenter study of the effect of treatment on outcome. J Bone Joint Surg Am.
2004;86:2121-34.
31. Rosenfeld SB, Herring JA, Chao JC. Legg-Calve-Perthes disease: a review of
cases with onset before six years of age. J Bone Joint Surg Am. 2007;89:2712-22.
32. Wiig O. Perthes’ disease in Norway. A prospective study on 425 patients. Acta
Orthop Suppl. 2009;80:1-44.
33. Eyre-Brook A. Osteochondritis deformans coxae juvenilis or Perthes’ disease:
the results of treatment by traction in recumbency. Br J Surg. 1936;24:166.
34. Harrison MH, Menon MP. Legg-Calvé-Perthes disease. The value of roentgen-
ographic measurement in clinical practice with special reference to the broomstick
plaster method. J Bone Joint Surg Am. 1966;48:1301-18.
35. Bobechko WP. The Toronto brace for Legg-Perthes disease. Clin Orthop Relat
Res. 1974;102:115-7.
36. Curtis BH, Gunther SF, Gossling HR, Paul SW. Treatment for Legg-Perthes dis-
ease with the Newington ambulation-abduction brace. J Bone Joint Surg Am.
1974;56:1135-46.
37. Harrison MH, Turner MH, Nicholson FJ. Coxa plana. Results of a new form of
splinting. J Bone Joint Surg Am. 1969;51:1057-69.
38. King EW, Fisher RL, Gage JR, Gossling HR. Ambulation-abduction treatment in
Legg-Calvé-Perthes disease (LCPD). Clin Orthop Relat Res. 1980;150:43-8.
39. Purvis JM, Dimon JH 3rd, Meehan PL, Lovell WW. Preliminary experience with
the Scottish Rite Hospital abduction orthosis for Legg-Perthes disease. Clin Orthop
Relat Res. 1980;150:49-53.
40. Vukasinovic Z, Spasovski D, Vucetic C, Cobeljic G, Zivkovic Z, Matanovic D.
Triple pelvic osteotomy in the treatment of Legg-Calve-Perthes disease. Int Orthop.
2009;33:1377-83.
41. Javid M, Wedge JH. Radiographic results of combined Salter innominate and
femoral osteotomy in Legg-Calvé-Perthes disease in older children. J Child Orthop.
2009;3:229-34.
42. Rab GT. Containment of the hip: a theoretical comparison of osteotomies. Clin
Orthop Relat Res. 1981;154:191-6.
43. Rab GT. Theoretical study of subluxation in early Legg-Calvé-Perthes disease.
J Pediatr Orthop. 2005;25:728-33.
44. Wiig O, Terjesen T, Svenningsen S. Prognostic factors and outcome of treatment
in Perthes’ disease: a prospective study of 368 patients with five-year follow-up.
J Bone Joint Surg Br. 2008;90:1364-71.
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E
45. Heikkinen E, Puranen J. Evaluation of femoral osteotomy in the treatment of
Legg-Calvé-Perthes disease. Clin Orthop Relat Res. 1980;150:60-8.
46. Bahmanyar S, Montgomery SM, Weiss RJ, Ekbom A. Maternal smoking during
pregnancy, other prenatal and perinatal factors, and the risk of Legg-Calvé-Perthes
disease. Pediatrics. 2008;122:e459-64.
47. Gordon JE, Schoenecker PL, Osland JD, Dobbs MB, Szymanski DA, Luhmann SJ.
Smoking and socio-economic status in the etiology and severity of Legg-Calvé-
Perthes’ disease. J Pediatr Orthop B. 2004;13:367-70.
48. Matsumoto T, Enomoto H, Takahashi K, Motokawa S. Decreased levels of IGF
binding protein-3 in serum from children with Perthes’ disease. Acta Orthop Scand.
1998;69:125-8.
49. Neidel J, Schönau E, Zander D, Rütt J, Hackenbroch MH. Normal plasma levels
of IGF binding protein in Perthes’ disease. Follow-up of previous report. Acta Orthop
Scand. 1993;64:540-2.
50. Liu YF, Chen WM, Lin YF, Yang RC, Lin MW, Li LH, Chang YH, Jou YS, Lin PY, Su
JS, Huang SF, Hsiao KJ, Fann CS, Hwang HW, Chen YT, Tsai SF. Type II collagen gene
variants and inherited osteonecrosis of the femoral head. N Engl J Med. 2005;352:
2294-301.
51. Arruda VR, Belangero WD, Ozelo MC, Oliveira GB, Pagnano RG, Volpon JB,
Annichino-Bizzacchi JM. Inherited risk factors for thrombophilia among children with
Legg-Calvé-Perthes disease. J Pediatr Orthop. 1999;19:84-7.
52. Eldridge J, Dilley A, Austin H, EL-Jamil M, Wolstein L, Doris J, Hooper WC,
Meehan PL, Evatt B. The role of protein C, protein S, and resistance to activated
protein C in Legg-Perthes disease. Pediatrics. 2001;107:1329-34.
53. Gruppo R, Glueck CJ, Wall E, Roy D, Wang P. Legg-Perthes disease in three
siblings, two heterozygous and one homozygous for the factor V Leiden mutation.
J Pediatr. 1998;132:885-8.
54. Szepesi K, Pósán E, Hársfalvi J, Ajzner E, Szücs G, Gáspár L, Csernátony Z,
Udvardy M. The most severe forms of Perthes’ disease associated with the homo-
zygous Factor V Leiden mutation. J Bone Joint Surg Br. 2004;86:426-9.
55. Vosmaer A, Pereira RR, Koenderman JS, Rosendaal FR, Cannegieter SC. Co-
agulation abnormalities in Legg-Calvé-Perthes disease. J Bone Joint Surg Am.
2010;92:121-8.
56. Hayek S, Kenet G, Lubetsky A, Rosenberg N, Gitel S, Wientroub S. Does
thrombophilia play an aetiological role in Legg-Calvé-Perthes disease? J Bone Joint
Surg Br. 1999;81:686-90.
57. Kealey WD, Mayne EE, McDonald W, Murray P, Cosgrove AP. The role of coag-
ulation abnormalities in the development of Perthes’ disease. J Bone Joint Surg Br.
2000;82:744-6.
58. Kenet G, Ezra E, Wientroub S, Steinberg DM, Rosenberg N, Waldman D, Hayek
S. Perthes’ disease and the search for genetic associations: collagen mutations,
Gaucher’s disease and thrombophilia. J Bone Joint Surg Br. 2008;90:1507-11.
59. López-Franco M, González-Morán G, De Lucas JC Jr, Llamas P, de Velasco JF,
Vivancos JC, Epeldegui-Torre T. Legg-perthes disease and heritable thrombophilia.
J Pediatr Orthop. 2005;25:456-9.
60. Sirvent N, Fisher F, el Hayek T, Appert A, Giudicelli H, Griffet J. Absence of
congenital prethrombotic disorders in children with Legg-Perthes disease. J Pediatr
Orthop B. 2000;9:24-7.
61. Atsumi T, Yamano K, Muraki M, Yoshihara S, Kajihara T. The blood supply of the
lateral epiphyseal arteries in Perthes’ disease. J Bone Joint Surg Br. 2000;82:392-8.
62. de Camargo FP, de Godoy RM Jr, Tovo R. Angiography in Perthes’ disease. Clin
Orthop Relat Res. 1984;191:216-20.
63. Théron J. Angiography in Legg-Calvé-Perthes disease. Radiology. 1980;135:
81-92.
64. Conway JJ. A scintigraphic classification of Legg-Calvé-Perthes disease. Semin
Nucl Med. 1993;23:274-95.
65. Lamer S, Dorgeret S, Khairouni A, Mazda K, Brillet PY, Bacheville E, Bloch J,
Pennecxot GF, Hassan M, Sebag GH. Femoral head vascularisation in Legg-Calvé-Perthes
disease: comparison of dynamic gadolinium-enhanced subtraction MRI with bone
scintigraphy. Pediatr Radiol. 2002;32:580-5.
66. Catterall A, Pringle J, Byers PD, Fulford GE, Kemp HB, Dolman CL, Bell HM,
McKibbin B, Rális Z, Jensen OM, Lauritzen J, Ponseti IV, Ogden J. A review of the
morphology of Perthes’ disease. J Bone Joint Surg Br. 1982;64:269-75.
67. Jonsater S. Coxa plana; a histo-pathologic and arthrografic study. Acta Orthop
Scand Suppl. 1953;12:5-98.
68. Kim HK, Su PH. Development of flattening and apparent fragmentation following
ischemic necrosis of the capital femoral epiphysis in a piglet model. J Bone Joint
Surg Am. 2002;84:1329-34.
69. Shapiro F, Connolly S, Zurakowski D, Menezes N, Olear E, Jimenez M, Flynn E,
Jaramillo D. Femoral head deformation and repair following induction of ischemic
necrosis: a histologic and magnetic resonance imaging study in the piglet. J Bone
Joint Surg Am. 2009;91:2903-14.
70. Sanchis M, Zahir A, Freeman MA. The experimental simulation of Perthes dis-
ease by consecutive interruptions of the blood supply to the capital femoral epiph-
ysis in the puppy. J Bone Joint Surg Am. 1973;55:335-42.
71. Zahir A, Freeman AR. Cartilage changes following a single episode of infarction
of the capital femoral epiphysis in the dog. J Bone Joint Surg Am. 1972;54:125-36.
 669
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
d
V O LU M E 94 -A N U M B E R 7 A P R I L 4, 2 012
d d
72. Inoue A, Freeman MA, Vernon-Roberts B, Mizuno S. The pathogenesis of
Perthes’ disease. J Bone Joint Surg Br. 1976;58:453-61.
73. Dolman CL, Bell HM. The pathology of Legg-Calvé-Perthes disease. A case
report. J Bone Joint Surg Am. 1973;55:184-8.
74. McKibbin B, Rális Z. Pathological changes in a case of Perthes’ disease. J Bone
Joint Surg Br. 1974;56:438-47.
75. Idiopathic osteonecrosis of the juvenile femoral head (Legg-Calve-Perthes dis-
ease). In: Milgram JW. Radiologic and histologic pathology of nontumorous diseases
of bones and joints. Northbrook: Northbrook Pub Co; 1990. p 1093-113.
76. Ponseti IV. Legg-Perthes disease; observations on pathological changes in two
cases. J Bone Joint Surg Am. 1956;38:739-50.
77. Hofstaetter JG, Roschger P, Klaushofer K, Kim HK. Increased matrix minerali-
zation in the immature femoral head following ischemic osteonecrosis. Bone.
2010;46:379-85.
78. Kim HK, Su PH, Qiu YS. Histopathologic changes in growth-plate cartilage fol-
lowing ischemic necrosis of the capital femoral epiphysis. An experimental investi-
gation in immature pigs. J Bone Joint Surg Am. 2001;83:688-97.
79. Koob TJ, Pringle D, Gedbaw E, Meredith J, Berrios R, Kim HK. Biomechanical
properties of bone and cartilage in growing femoral head following ischemic osteo-
necrosis. J Orthop Res. 2007;25:750-7.
80. Pringle D, Koob TJ, Kim HK. Indentation properties of growing femoral head
following ischemic necrosis. J Orthop Res. 2004;22:122-30.
81. Phemister DB. Treatment of the necrotic head of the femur in adults. J Bone
Joint Surg Am. 1949;31:55-66.
82. Aya-ay J, Athavale S, Morgan-Bagley S, Bian H, Bauss F, Kim HK. Retention,
distribution, and effects of intraosseously administered ibandronate in the infarcted
femoral head. J Bone Miner Res. 2007;22:93-100.
83. Kim HK, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to
decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res.
2006;21:1946-54.
84. Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F. Ibandronate for
prevention of femoral head deformity after ischemic necrosis of the capital femoral
epiphysis in immature pigs. J Bone Joint Surg Am. 2005;87:550-7.
85. Little DG, McDonald M, Sharpe IT, Peat R, Williams P, McEvoy T. Zoledronic acid
improves femoral head sphericity in a rat model of perthes disease. J Orthop Res.
2005;23:862-8.
86. Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic
acid treatment results in retention of femoral head structure after traumatic osteo-
necrosis in young Wistar rats. J Bone Miner Res. 2003;18:2016-22.
87. Carlson CS, Meuten DJ, Richardson DC. Ischemic necrosis of cartilage in spon-
taneous and experimental lesions of osteochondrosis. J Orthop Res. 1991;9:317-29.
88. McKibbin B, Holdsworth FW. The nutrition of immature joint cartilage in the
lamb. J Bone Joint Surg Br. 1966;48:793-803.
89. Kim HK, Bian H, Aya-ay J, Garces A, Morgan EF, Gilbert SR. Hypoxia and
HIF-1alpha expression in the epiphyseal cartilage following ischemic injury to the
immature femoral head. Bone. 2009;45:280-8.
90. Kim HK, Bian H, Randall T, Garces A, Gerstenfeld LC, Einhorn TA. Increased
VEGF expression in the epiphyseal cartilage after ischemic necrosis of the capital
femoral epiphysis. J Bone Miner Res. 2004;19:2041-8.
91. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples
hypertrophic cartilage remodeling, ossification and angiogenesis during endochon-
dral bone formation. Nat Med. 1999;5:623-8.
92. Vandermeer JS, Kamiya N, Aya-ay J, Garces A, Browne R, Kim HK. Local ad-
ministration of ibandronate and bone morphogenetic protein-2 after ischemic
osteonecrosis of the immature femoral head: a combined therapy that stimulates
bone formation and decreases femoral head deformity. J Bone Joint Surg Am.
2011;18:905-13.
93. Bergmann G, Deuretzbacher G, Heller M, Graichen F, Rohlmann A, Strauss J,
Duda GN. Hip contact forces and gait patterns from routine activities. J Biomech.
2001;34:859-71.
94. Bergmann G, Graichen F, Rohlmann A. Hip joint loading during walking and
running, measured in two patients. J Biomech. 1993;26:969-90.
95. Song KM, Bjornson KF, Cappello T, Coleman K. Use of the StepWatch activity
monitor for characterization of normal activity levels of children. J Pediatr Orthop.
2006;26:245-9.
96. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation.
Nature. 2003;423:337-42.
P AT H O P H Y S I O L O G Y A N D N E W S T R AT E G I E S F O R T H E
T R E AT M E N T O F L E G G -C A LV É - P E R T H E S D I S E A S E
97. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas
P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti
S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in post-
menopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
98. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL,
Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino
FH. Bisphosphonates: an update on mechanisms of action and how these relate to
clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-57.
99. Kim HK, Sanders M, Athavale S, Bian H, Bauss F. Local bioavailability and
distribution of systemically (parenterally) administered ibandronate in the infarcted
femoral head. Bone. 2006;39:205-12.
100. Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, Munns CF. Systemic
effects of zoledronic acid in children with traumatic femoral head avascular necrosis
and Legg-Calve-Perthes disease. Bone. 2009;45:898-902.
101. Giannoudis PV, Einhorn TA. Bone morphogenetic proteins in musculoskeletal
medicine. Injury. 2009;40 Suppl 3:S1-3.
102. Mont MA, Ragland PS, Biggins B, Friedlaender G, Patel T, Cook S, Etienne G,
Shimmin A, Kildey R, Rueger DC, Einhorn TA. Use of bone morphogenetic proteins for
musculoskeletal applications. An overview. J Bone Joint Surg Am. 2004;86 Suppl
2:41-55.
103. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893-9.
104. Simank HG, Manggold J, Sebald W, Ries R, Richter W, Ewerbeck V, Sergi C.
Bone morphogenetic protein-2 and growth and differentiation factor-5 enhance the
healing of necrotic bone in a sheep model. Growth Factors. 2001;19:247-57.
105. Tang TT, Lu B, Yue B, Xie XH, Xie YZ, Dai KR, Lu JX, Lou JR. Treatment of
osteonecrosis of the femoral head with hBMP-2-gene-modified tissue-engineered
bone in goats. J Bone Joint Surg Br. 2007;89:127-9.
106. Mont MA, Jones LC, Elias JJ, Inoue N, Yoon TR, Chao EY, Hungerford DS. Strut-
autografting with and without osteogenic protein-1: a preliminary study of a canine
femoral head defect model. J Bone Joint Surg Am. 2001;83:1013-22.
107. Lieberman JR, Conduah A, Urist MR. Treatment of osteonecrosis of the fem-
oral head with core decompression and human bone morphogenetic protein. Clin
Orthop Relat Res. 2004;429:139-45.
108. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn
JM, Gillespie MT, Martin TJ, Suda T, Takahashi N. Bone morphogenetic protein 2
stimulates osteoclast differentiation and survival supported by receptor activator of
nuclear factor-kappaB ligand. Endocrinology. 2001;142:3656-62.
109. Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M, Kronenberg
HM, Feng JQ, Mishina Y. Disruption of BMP signaling in osteoblasts through
type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res. 2008;23:
2007-17.
110. Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama
Y, Yabe Y, Kumegawa M, Hakeda Y. Direct stimulation of osteoclastic bone re-
sorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in
mature osteoclasts. Bone. 2000;27:479-86.
111. Seeherman HJ, Li XJ, Bouxsein ML, Wozney JM. rhBMP-2 induces transient
bone resorption followed by bone formation in a nonhuman primate core-defect
model. J Bone Joint Surg Am. 2010;92:411-26.
112. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate,
in the treatment of AVN of the hip. A prospective open-label study. Rheumatology
(Oxford). 2005;44:352-9.
113. Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of
avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br.
2009;91:1013-8.
114. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to
prevent early collapse of the femoral head in patients with nontraumatic osteone-
crosis. A randomized clinical study. J Bone Joint Surg Am. 2005;87:2155-9.
115. Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate
prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res.
2006;443:273-9.
116. Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG. Intra-
venous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in
adolescents. J Bone Joint Surg Am. 2007;89:1727-34.
117. Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C. Use of bis-
phosphonates for the treatment of osteonecrosis as a complication of therapy
for childhood acute lymphoblastic leukaemia (ALL). Pediatr Blood Cancer. 2010;
54:934-40.